Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Phytosterol + hawthorn** is a combination product consisting of phytosterols (plant-derived sterols) and hawthorn (typically, extracts from Crataegus species) formulated for oral intake, most commonly as a dietary supplement for the support of cardiovascular health and the management of blood lipid levels. Phytosterols inhibit the intestinal absorption of dietary cholesterol, leading to lower blood LDL cholesterol. Hawthorn is rich in flavonoids and triterpenic acids and is reported to exert multiple cardiovascular benefits, including mild blood pressure and cholesterol-lowering actions, antioxidant, anti-inflammatory, and possible mild positive inotropic (heart-strengthening) effects. Preclinical and limited clinical studies suggest these two ingredients may have additive lipid-lowering effects, but robust clinical efficacy and safety data on the combination are lacking. The combination is most often positioned for individuals seeking non-prescription support for hyperlipidemia or mild cardiovascular symptoms, and is not a pharmaceutical-grade drug approved for specific cardiovascular indications[3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phytosterol + hawthorn.